Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 6Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Nasopharyngeal Carcinoma 2Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Resectable Non-small Cell Lung Cancer 1Radiation Pneumonitis 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1MSI-H 1Lung Neoplasms 1HER2+ Breast Cancer 1Gastrointestinal Diseases 1Esophageal Diseases 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1

Interventions

sintilimab 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Squamous NSCLC × sintilimab × Clear all
NCT03629925 2023-02-28

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
357 enrolled 14 charts
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡